BRPI0813309B8 - capsídeo, mistura de capsídeos e proteína quimérica - Google Patents

capsídeo, mistura de capsídeos e proteína quimérica

Info

Publication number
BRPI0813309B8
BRPI0813309B8 BRPI0813309A BRPI0813309A BRPI0813309B8 BR PI0813309 B8 BRPI0813309 B8 BR PI0813309B8 BR PI0813309 A BRPI0813309 A BR PI0813309A BR PI0813309 A BRPI0813309 A BR PI0813309A BR PI0813309 B8 BRPI0813309 B8 BR PI0813309B8
Authority
BR
Brazil
Prior art keywords
epitope
capsid
chimeric protein
mixture
amino acid
Prior art date
Application number
BRPI0813309A
Other languages
English (en)
Inventor
Kondo Kazunari
Kanda Tadahito
Original Assignee
Japan Health Sciences Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Health Sciences Found filed Critical Japan Health Sciences Found
Publication of BRPI0813309A2 publication Critical patent/BRPI0813309A2/pt
Publication of BRPI0813309B1 publication Critical patent/BRPI0813309B1/pt
Publication of BRPI0813309B8 publication Critical patent/BRPI0813309B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

capsídeo, mistura de capsídeos, proteína quimérica, métodos para produzir o capsídeo, e para produzir a mistura de capsídeos, e, complexo de hemocianina de lapa e epítopo l2 de papilomavírus humano 16. descreve-se um antígeno de vacina capaz de induzir uma reação cruzada e anticorpo neutralizante dirigidos contra um papilomavírus humano de tipo de .alto risco. descreve-se especificamente: uma proteína quimérica compreendendo um l2-epítopo de papilomavírus humano (hpv) 10 tipo-16 inserido em uma região de laço de uma. proteína tipo l1 de. papilomavíms humano 16; e um capsídeo que é um agregado da proteína quimérica. a região de laço em- que o epítopo l2 deve ser inserido está localizada entre um resíduo de aminoácido em posição 430 e um resíduo de aminoácido em posição-433. o epítopo l2 tem uma sequência de aminoácidos representada por qualquer uma das seguinte fórmulas: lyktckqagtcppdiipkveg (epítopo l2 18-32); gglgigtgsgtggrtgyipl (epítopo l2 56-75); e dpvgpldpsjvslveessfi (epítopo l2 96-115).
BRPI0813309A 2007-06-26 2008-06-25 capsídeo, mistura de capsídeos e proteína quimérica BRPI0813309B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007167154 2007-06-26
JP2007-167154 2007-06-26
PCT/JP2008/061569 WO2009001867A1 (ja) 2007-06-26 2008-06-25 高リスク群ヒトパピローマウイルスに対する交差性中和抗体を誘導するワクチン抗原

Publications (3)

Publication Number Publication Date
BRPI0813309A2 BRPI0813309A2 (pt) 2014-12-23
BRPI0813309B1 BRPI0813309B1 (pt) 2020-10-06
BRPI0813309B8 true BRPI0813309B8 (pt) 2021-05-25

Family

ID=40185679

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813309A BRPI0813309B8 (pt) 2007-06-26 2008-06-25 capsídeo, mistura de capsídeos e proteína quimérica

Country Status (14)

Country Link
US (1) US9023364B2 (pt)
EP (1) EP2168977B1 (pt)
JP (1) JP5540329B2 (pt)
KR (2) KR101624358B1 (pt)
CN (1) CN101835796A (pt)
AU (1) AU2008268014B2 (pt)
BR (1) BRPI0813309B8 (pt)
CA (1) CA2691745C (pt)
ES (1) ES2688474T3 (pt)
MX (1) MX2009014246A (pt)
MY (1) MY152175A (pt)
NZ (1) NZ582271A (pt)
RU (1) RU2471807C2 (pt)
WO (1) WO2009001867A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2199301A1 (en) 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof
EP2416798B1 (en) * 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
CN102497880A (zh) 2009-06-25 2012-06-13 葛兰素史密丝克莱恩生物有限公司 新的人乳头状瘤病毒(hpv)蛋白构建体及其在预防hpv疾病中的用途
WO2011160848A1 (en) * 2010-06-23 2011-12-29 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechtes Rearranged tt virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
WO2012090895A1 (ja) 2010-12-27 2012-07-05 財団法人ヒューマンサイエンス振興財団 ヒトパピローマウィルス（hpv）ｌ２蛋白質を認識するモノクローナル抗体とそれを使用したhpv中和抗体価測定法
US20150344529A1 (en) * 2012-12-25 2015-12-03 The Chemo-Sero-Therapeutic Research Institute Vaccine for hpv infection and/or hepatitis b comprising hpv/hbs chimeric protein as active ingredient
CN107188966B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN114716561B (zh) * 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途
CN114716562B (zh) * 2021-01-04 2023-11-10 中国医学科学院基础医学研究所 一种人乳头瘤病毒58型嵌合蛋白及其用途
CN114716560B (zh) * 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途
CN115337388A (zh) * 2022-07-01 2022-11-15 南方医科大学 一种抗菌和预防hpv病毒的按需释放凝胶及其制备方法
CN115724950B (zh) * 2022-11-15 2023-10-03 怡道生物科技(苏州)有限公司 Hpv6型衣壳蛋白l1单克隆抗体、制备方法及应用
CN116199772B (zh) * 2022-11-16 2023-10-17 怡道生物科技(苏州)有限公司 Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE328068T1 (de) 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
RU2229307C1 (ru) * 2002-10-22 2004-05-27 ООО "Фирма"БиоМедИнвест" Композиция рекомбинантных белков, способ получения такой композиции, фармацевтический набор реагентов для иммунотерапии и профилактической вакцинации опухолевых заболеваний аногенитальной сферы, способ иммунотерапии и профилактической вакцинации на его основе
WO2005097987A1 (ja) * 2004-04-09 2005-10-20 Japan Health Sciences Foundation 粘膜指向性ヒトパピローマウイルス群の感染予防ワクチン抗原
US20060286591A1 (en) 2005-06-21 2006-12-21 Medimmune Vaccines, Inc. Methods and compositions for expressing negative-sense viral RNA in canine cells
JP4825958B2 (ja) 2005-08-10 2011-11-30 財団法人ヒューマンサイエンス振興財団 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原

Also Published As

Publication number Publication date
BRPI0813309B1 (pt) 2020-10-06
CA2691745C (en) 2017-08-15
MX2009014246A (es) 2010-03-31
NZ582271A (en) 2012-03-30
AU2008268014A1 (en) 2008-12-31
MY152175A (en) 2014-08-15
WO2009001867A1 (ja) 2008-12-31
RU2009148037A (ru) 2011-06-27
EP2168977A4 (en) 2013-12-18
AU2008268014B2 (en) 2013-10-31
US20100183648A1 (en) 2010-07-22
KR101624358B1 (ko) 2016-05-26
EP2168977B1 (en) 2018-08-08
JPWO2009001867A1 (ja) 2010-08-26
KR20100029216A (ko) 2010-03-16
CN101835796A (zh) 2010-09-15
US9023364B2 (en) 2015-05-05
EP2168977A1 (en) 2010-03-31
CA2691745A1 (en) 2008-12-31
RU2471807C2 (ru) 2013-01-10
BRPI0813309A2 (pt) 2014-12-23
ES2688474T3 (es) 2018-11-02
JP5540329B2 (ja) 2014-07-02
KR20150090285A (ko) 2015-08-05

Similar Documents

Publication Publication Date Title
MX2009014246A (es) Antigeno de vacuna con la capacidad de inducir anticuerpo de neutralizacion y reaccion cruzada contra virus de papiloma humano del tipo de alto riesgo.
Guo et al. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer
Kreimer Prospects for prevention of HPV-driven oropharynx cancer
MY139896A (en) Improved prrs vaccines
CL2011003271A1 (es) Polipeptido l1 del virus de papiloma humano (hpv) tipo 18 que comprende cuando menos un peptido que comprende un epitopo de un polipeptido l2; capsomero; particula parecida a virus (vlp); composicion inmunogenica; molecula de acido nucleico; polipeptido; metodo para producir polipeptido; metodo para producir composicion inmunogenica.
PH12017500437A1 (en) Methods for synthesis of graphene derivatives and functional materials from asphaltenes, graphene derivatives, 2d materials and applications of use
CL2012000585A1 (es) Composición inmunogénica que comprende un compuesto agonista de un receptor tipo toll 7 (tlr7) o una sal de este, un antígeno, y un adyuvante que contiene aluminio; método para mejorar la efectividad de una composición inmunogénica que comprende adicionar dicha composición que contiene un agonista de tlr7; y su uso como inmunoestimulante.
AU2015204503A8 (en) Novel vaccines against HPV and HPV-related diseases
NZ601793A (en) Methods and compositions for diagnosis and treatment of cancer
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
EA201170153A1 (ru) Микроциклические производные индола, пригодные в качестве ингибиторов вируса гепатита с
BR112015007818A2 (pt) composto, composição farmacêutica, e, uso de um composto e de uma composição farmacêutica
Peng et al. Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
PE20230349A1 (es) Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas
MX2015009507A (es) Antigenos recombinantes del porcine circovirus 2 (pcv-2) para formulaciones de vacuna, kit de diagnostico y uso.
CY1113830T1 (el) Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
BR112015021162A2 (pt) peptídeo tendo 5 epítopos de ctl ligados
CU24682B1 (es) Una composición de vacuna multivalente compuesta por una mezcla de antígenos provenientes de virus de polio y rotavirus inactivados
MX2011002309A (es) Anticuerpos de aves especificos para virus de influenza y metodos tecnologicamente sencillos de su fabricacion y uso.
MX2010003220A (es) Proteinas inmunogenicas de membrana exterior derivada de genoma de leptospira y composiciones y metodos basados en las mismas.
Du et al. Long-term humoral immunity induced by CVC1302-adjuvanted serotype O foot-and-mouth disease inactivated vaccine correlates with promoted T follicular helper cells and thus germinal center responses in mice
BRPI0800485B8 (pt) vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
Kohler Novel vaccine concept based on back-boost effect in viral infection

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: JAPAN HEALTH SCIENCES FOUNDATION (JP)

B25A Requested transfer of rights approved

Owner name: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2832 DE 15-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.